PRODUCT INFORMATION



JZL 195

Item No. 13668

Sold under license from The Scripps Research Institute

CAS Registry No.: 1210004-12-8

Formal Name: 4-nitrophenyl-4-(3-phenoxybenzyl)

piperazine-1-carboxylate

MF: $C_{24}H_{23}N_3O_5$ FW: 433.5 **Purity:** ≥98% λ_{max} : 273 nm A crystalline solid UV/Vis.: Supplied as:

Storage: -20°C Stability: ≥4 vears

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JZL 195 is supplied as a crystalline solid. A stock solution may be made by dissolving the JZL 195 in the solvent of choice, which should be purged with an inert gas. JZL 195 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of JZL 195 in these solvents is approximately 1.25 and 5 mg/ml, respectively.

Description

Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) mediate the hydrolysis of the endocannabinoids arachidonoyl ethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG), respectively. JZL 195 is a potent inhibitor of both FAAH and MAGL ($IC_{50}s = 2$ and 4 nM, respectively). It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL in vivo, consistent with a covalent mechanism of activation.¹ The in vivo inhibitory actions of JZL 195 against FAAH and MAGL are comparable to those of the selective inhibitors PF-3845 (Item No. 13279) and JZL 184 (Item No. 13158), respectively. Through its inhibitory actions, JZL 195 simultaneously augments brain levels of AEA and 2-AG, producing antinociceptive, cataleptic, and hypomotility effects like those produced by direct CB₁ agonists. ¹

Reference

1. Long, J.Z., Nomura, D.K., Vann, R.E., et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. PNAS 106(48) 20270-20275 (2009).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 03/28/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM